PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Nov 12, 2025
Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026
Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results
Read more at globenewswire.comNASDAQ:PYPD (12/19/2025, 2:34:00 PM)
3.95
+0.03 (+0.77%)
Find more stocks in the Stock Screener
